Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2017 08:30 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy

EMERYVILLE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive topline data from the Phase 1b clinical trial of ADS-4101 (lacosamide)...
August 24, 2017 16:16 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine)...
August 08, 2017 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results

EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. ...
August 01, 2017 14:33 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8, 2017

EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August...
July 10, 2017 16:32 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Inducement Grant to New Chief Financial Officer

EMERYVILLE, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Financial Officer, Alfred G....
June 28, 2017 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Appoints New Chief Financial Officer

EMERYVILLE, Calif, June 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Alfred G. Merriweather as Chief Financial Officer, reporting to...
June 12, 2017 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology

--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson’s Disease Patients with Levodopa-induced Dyskinesia -- --...
June 08, 2017 16:10 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks

-- New subgroup analyses showed that patients previously treated with amantadine IR received benefit of ADS-5102 comparable to patients previously treated with placebo -- -- New Drug Application...
June 01, 2017 12:31 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at Two Upcoming Investor Conferences

EMERYVILLE, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., the company’s Chairman and Chief Executive Officer, is...
May 22, 2017 08:30 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy

-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study...